← Back to Search

Other

ASP8062 for Alcoholism

Phase 2

Waitlist Available

Research Sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 3

Awards & highlights

Study Summary

This trial is testing a new drug to see if it can help people with alcohol addiction by reducing how much they crave alcohol.

Eligible Conditions

Alcoholism
Alcohol Consumption

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 3

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 3

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 3 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Alcohol Craving

Side effects data

From 2018 Phase 2 trial • 183 Patients • NCT03092726

29%

Dizziness

15%

Headache

Nausea

Urinary tract infection

100%

80%

60%

40%

20%

Study treatment Arm

Placebo

ASP8062 30 mg

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Active MedicationExperimental Treatment1 Intervention

Group II: Matching PlaceboPlacebo Group1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

ASP8062

2021

Completed Phase 2

~330

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Institute on Alcohol Abuse and Alcoholism (NIAAA)Lead Sponsor

799 Previous Clinical Trials

1,362,451 Total Patients Enrolled

422 Trials studying Alcoholism

985,148 Patients Enrolled for Alcoholism

Astellas Pharma IncIndustry Sponsor

691 Previous Clinical Trials

232,154 Total Patients Enrolled

Raye Litten, Ph.D.Study DirectorNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current participant count of this research?

"Astellas Pharma Inc is launching the clinical trial from multiple sites that include Brown University in Providence, Rhode island and University of Colorado in Aurora, Colorado. To complete this study, 60 individuals must be recruited who meet all inclusion criteria."

Answered by AI

Is enrollment open at this time for the trial?

"Accessing clinicaltrials.gov, it is evident that this medical trial is currently in search of participants and was first posted on December 13th 2021 with a more recent update occurring June 20th 2022."

Answered by AI

What potential hazards should be taken into consideration when using ASP8062?

"ASP8062 was assigned a safety rating of 2, as the trial is currently in its second phase and there has been some evidence that demonstrates it's safe but no data confirming efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Human Laboratory Study of ASP8062 for Alcohol Use Disorder

2021. "Human Laboratory Study of ASP8062 for Alcohol Use Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05096117.